Pancreatic ductal adenocarcinoma (pdac)

Show results for

Unknown (5037)
Genomics (1465)
Transcriptomics (901)
Proteomics (221)
Other (87)
Clinical (24)
Methylation profiling (16)
Metabolomics (16)
Genomic (2)

Organisms

Homo sapiens (901)
Mus musculus (541)
synthetic construct (12)
Mus (6)
mouse gut metagenome (1)
Danio rerio (1)
blank sample (1)
Acyrthosiphon pisum (1)
Rattus norvegicus (1)

Organisms

Homo sapiens (608)
Mus musculus (401)
Mus (6)
mouse gut metagenome (1)
Rattus norvegicus (1)
Danio rerio (1)

Repository

ENA (1241)
geo (984)
biostudies-arrayexpress (180)
pride (172)
EGA (57)
iProX (23)
MassIVE (21)
MetaboLights (13)
ExpressionAtlas (4)
NODE (4)
GNPS (3)
jPOST (3)
dbGaP (2)
EVA (1)

Tissue

Cell culture (68)
Pancreas (38)
Epithelial cell (21)
Permanent cell line cell (21)
Pancreatic ductal cell (19)
Pancreatic ductal adenocarcinoma cell (9)
Blood serum (8)
Liver (5)
Blood plasma (5)
Epithelium of pancreatic duct (5)
Fibroblast (5)
Cell suspension culture (4)
Pancreatic ductal adenocarcinoma cell line (4)
Pancreatic stellate cell (4)
Epithelial cell of pancreas (3)
Lung (3)
Malignant cell (3)
Pancreatic duct (3)
Pancreatic ductal carcinoma cell (3)
Adipose tissue (2)
Colon (2)
Heart (2)
Macrophage (2)
Neoplastic cell (2)
Pancreatic adenocarcinoma cell line (2)
Pancreatic cancer cell (2)
Primary cell (2)
Spleen (2)
Pancrease (1)
Pancreatic ductal adenocarcinoma tissues and cells (1)

Disease

Pancreatic ductal adenocarcinoma (60)
Pancreatic cancer (29)
Pancreatic ductal carcinoma (17)
Carcinoma (9)
Pancreas adenocarcinoma (5)
Pancreatic carcinoma (4)
Lung Neoplasms (4)
Normal (3)
Carcinoma, Renal Cell (3)
Colorectal Neoplasms (3)
Neoplasms (3)
Pancreatic ductal adenocarcinoma liver metastasis (2)
Primary pancreatic ductal adenocarcinoma (2)
Adenocarcinoma (2)
Cholangiocarcinoma (2)
Perineural invasion (1)
Chronic pancreatitis (1)
Adenocarcinoma (1)
Carcinoma, Non-Small-Cell Lung (1)
Carcinoma, Squamous Cell (1)
Gastrointestinal Neoplasms (1)
Melanoma (1)
Metastatic colorectal cancer (1)
Peutz-Jeghers Syndrome (1)
Cachexia (1)
Colon cancer (1)
Colorectal cancer (1)
Lung occult adenocarcinoma (1)
Non-small cell lung carcinoma (1)
Wounds and Injuries (1)

Technology Type

Mass Spectrometry (172)
Shotgun proteomics (89)
Bottom-up proteomics (42)
Data-dependent acquisition (18)
Affinity purification coupled with mass spectrometry proteomics (16)
Data-independent acquisition (14)
SWATH MS (11)
Mass spectrometry (9)
Gel-based experiment (5)
Mass spectrometry assay (4)
SRM/MRM (4)
All-ion fragmentation (2)
DiaPASEF (2)
Immunopeptidomics (2)
AB SOLiD 4 System, Illumina HiSeq 2500, Illumina HiSeq 2000, AB SOLiD System 3.0 (1)
HiSeq X Ten, Illumina HiSeq 4000, Illumina HiSeq 2500, ILLUMINA (1)
Nanostring cancer pathway, Nanostring Cancer Immune, ILLUMINA, Affymetrix GeneChipÂ® Human Transcriptome Array 2.0, Illumina HiSeq 4000 (1)
Chemical cross-linking coupled with mass spectrometry proteomics (1)
MSE (1)
Proteogenomics (1)
Top-down proteomics (1)

Instrument Platform

Illumina NovaSeq 6000 (10)
Illumina HiSeq 2500 (7)
Orbitrap Fusion Lumos (7)
NextSeq 550 (6)
Q Exactive (6)
Illumina HiSeq 2000 (5)
NextSeq 500 (5)
Illumina NovaSeq X (3)
Illumina HiSeq 4000 (3)
Q Exactive HF (3)
Q-Exactive (2)
Shimadzu Nexera LC-30AD UHPLC system (2)
Orbitrap Exploris 480 (2)
NextSeq 550 (Illumina). (1)
Agilent TapeStation (1)
Agilent Bioanalyzer 2100 (or TapeStation); Qubit 4 Fluorometer (Thermo Fisher Scientific) (1)
NanoDrop ND-1000 spectrophotometer (1)
BD Rhapsody Sequence Analysis Pipeline (1)
Aurora Cytek Cs 5L (1)
Whole Transcriptome v2 kit (1)
BD Rhapsody (1)
Element AVITI (1)
Illumina iScan-Scanner (1)
Illumina Genome Analyzer IIx (1)
None (1)
DNBSEQ-G400 (1)
Orbitrap Fusion (1)
Orbitrap Fusion ETD (1)
Q Exactive HF-X (1)
Q Exactive Plus (1)

Publication Date

2026 (260)
2025 (244)
2024 (209)
2023 (137)
2022 (95)
2021 (79)
2020 (67)
2016 (48)
2015 (45)
2019 (39)
2014 (33)
2013 (30)
2012 (30)
2017 (27)
2018 (25)
2011 (16)
2009 (5)
2008 (4)
2010 (3)
2007 (3)
2006 (1)

CHEBI ID

CHEBI:15354 (3)
CHEBI:16856 (3)
CHEBI:16919 (3)
CHEBI:24813 (3)
CHEBI:28946 (3)
CHEBI:116314 (2)
CHEBI:133185 (2)
CHEBI:142440 (2)
CHEBI:143243 (2)
CHEBI:15355 (2)
CHEBI:15428 (2)
CHEBI:15676 (2)
CHEBI:15724 (2)
CHEBI:15727 (2)
CHEBI:15756 (2)
CHEBI:15760 (2)
CHEBI:15891 (2)
CHEBI:15901 (2)
CHEBI:15918 (2)
CHEBI:15956 (2)
CHEBI:16020 (2)
CHEBI:16040 (2)
CHEBI:16163 (2)
CHEBI:16244 (2)
CHEBI:16344 (2)
CHEBI:16359 (2)
CHEBI:16393 (2)
CHEBI:16410 (2)
CHEBI:16449 (2)
CHEBI:16467 (2)

Metabolite Name

Beta-Alanine (3)
Choline (3)
Creatine (3)
Glycerophosphocholine (3)
Glycine (3)
1-Methylhistidine (2)
5-Hydroxy-tryptophan (2)
5-Hydroxylysine (2)
Acetylcarnitine (2)
Alanine (2)
Anserine (2)
Arginine (2)
Carnitine (2)
Glutarylcarnitine (2)
Histidine (2)
Homoserine (2)
Hypoxanthine (2)
Kynurenine (2)
L-Arginine (2)
L-Methionine (2)
L-Threonine (2)
L-Tryptophan (2)
L-Tyrosine (2)
Lactate (2)
Norvaline (2)
Pyridoxine (2)
S-(1,2-dicarboxyethyl)glutathione (2)
Sarcosine (2)
Serine (2)
Tyramine (2)

First Public Date

2026 (255)
2025 (242)
2024 (197)
2023 (133)
2022 (86)
2020 (77)
2021 (66)
2014 (51)
2019 (47)
2017 (27)
2018 (22)
2015 (19)
2016 (16)
2013 (3)

Modification

2x(15)N labeled L-lysine (1)
4x(15)N labeled L-arginine (1)

Study status

Recruiting (13)
Active, not recruiting (5)
Completed (2)
Terminated (2)
Not yet recruiting (1)
Ongoing (1)

Study type

Transcription profiling by array (100)
RNA-seq of coding RNA (30)
Interventional (22)
ChIP-seq (10)
Comparative genomic hybridization by array (8)
RNA-seq of coding RNA from single cells (8)
Methylation profiling by array (5)
Cell line - High-throughput sequencing (3)
Genotyping by array (3)
RNA-seq of non coding RNA (3)
Observational (2)
Unknown experiment type (1)
Human - High-throughput sequencing (1)
High-throughput sequencing (1)
Animal - High-throughput sequencing (1)
Transcription profiling by RT-PCR (1)
Spatial transcriptomics by high-throughput sequencing (1)
Bisulfite-seq (1)
ATAC-seq (1)
DNA-seq (1)
RNA-seq of total RNA (1)

Release Date

2022 (675)
2025 (673)
2023 (648)
2024 (613)
2021 (604)
2020 (487)
2019 (332)
2018 (224)
2016 (215)
2017 (210)
2015 (162)
2026 (110)
2014 (92)
2013 (58)
2012 (47)
2011 (34)
2010 (10)
2008 (9)
2009 (8)
2007 (4)
2006 (2)

Lab affiliation

Amsterdam UMC, Vrije Universiteit Amsterdam, Medical Oncology, Cancer Center Amsterdam, OncoProteomics Laboratory, Amsterdam, Netherlands (7)
Centre for Cancer Cell & Molecular Biology, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK. (5)
Lineberger Comprehensive Cancer Center at UNC Chapel Hill (4)
Daglig leder, PROMEC Institutt for klinisk og molekylær medisin lars.hagen@ntnu.no 73598508 72573342 Laboratoriesenteret, 231.04.008, Øya, Erling Skjalgssons gate 1 (3)
University of Manchester (3)
CRUK -CRUK Scotland nstitute for Cancer Research - Switchback Rd, Bearsden, Glasgow G61 1BD - United Kingdom (2)
Centre for Cancer Cell & Molecular Biology Barts Cancer Institute Queen Mary University of London Charterhouse Square London EC1M 6BQ U.K. (2)
Department of Biochemistry and Molecular Biology and the Biomedicine Discovery Institute; Monash University; Clayton 3800; Victoria; Australia (2)
Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center (2)
Faculty of Biology, Medicine & Health, Manchester Cell-Matrix Centre, Manchester Academic Health Science Centre, University of Manchester, Michael Smith Building, Oxford Road, Manchester, M13 9PT, United Kingdom (2)
General Manager of PROMEC Department of Clinical and Molecular Medicine +4773598508 +4772573342 Laboratoriesenteret, 231.04.008, Øya, Erling Skjalgssons gate 1 Norway (2)
Head of Laboratory of Neuro-Oncology, Neurology, Clinical & Cancer Proteomics (2)
Johns Hopkins University (2)
Personalized Genomic Medicine Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB) (2)
Professor and Vice Chairman for Research Department of Biochemistry and Molecular Genetics Co-Leader, Experimental Therapeutics Program UAB O'Neal Comprehensive Cancer Center Hugh Kaul Human Genetics Building, Kaul 504A The University of Alabama at Birmingham Birmingham, Alabama (2)
Tianjin Medical University Cancer Institute and Hospital (2)
1 Department of Hepatobiliary & Pancreatic Surgery, Zhongnan Hospital of Wuhan University, Wuhan, 430071, PR China. 2 Clinical Medicine Research Center for Minimally Invasive Procedure of Hepatobiliary & Pancreatic Diseases of Hubei Province, Hubei, PR China. 3 Taikang Center for Life and Medical Sciences of Wuhan University (1)
1Department of Hepatobiliary & Pancreatic Surgery, Zhongnan Hospital of Wuhan University, Wuhan, 430071, PR China. 2Clinical Medicine Research Center for Minimally Invasive Procedure of Hepatobiliary & Pancreatic Diseases of Hubei Province, Hubei, PR China. 3Taikang Center for Life and Medical Sciences of Wuhan University (1)
Acting Head of Proteomics (1)
AmsterdamUMC, Vrije Universiteit Amsterdam, Medical Oncology, Cancer Center Amsterdam, OncoProteomics Laboratory, Amsterdam, The Netherlands (1)
Assistant Professor of Biological Sciences Augusta University C2014 Science Hall 2500 Walton Way, Augusta-GA (1)
Bavarian Center for Biomolecular Mass Spectrometry (BayBioMS) School of Life Sciences Technical University Munich (TUM) Gregor-Mendel-Straße 4 85354 Freising GERMANY Bavarian Center for Biomolecular Mass Spectrometry Technische Universität München Gregor-Mendel-Straße 4 85354 Freising DEUTSCHLAND / GERMANY (1)
Bavarian Center for Biomolecular Mass Spectrometry (BayBioMS) Technical University Munich (TUM) Gregor-Mendel-Straße 4 85354 Freising GERMANY (1)
Bertis Inc. (1)
Biotech Research and Innovation Centre (BRIC), University of Copenhagen (UCPH), Copenhagen, Denmark (1)
Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Old Road, University of Oxford, Oxford OX3 7LD, UK (1)
Bowel Cancer and biomarker laboratory (1)
CRUK -CRUK Scotland Institute for Cancer Research - Switchback Rd, Bearsden, Glasgow G61 1BD - United Kingdom (1)
CRUK Beatson Institute, Switchback Road, Glasgow G61 1BD, UK. (1)
Cancer Pharmacology Lab, Fondazione Pisana per la Scienza, San Giuliano, Pisa, Italy (1)

Location

United States (16)
France (7)
Spain (7)
Australia (5)
Germany (5)
Italy (5)
United Kingdom (5)
Belgium (4)
Canada (4)
South Korea (3)
Denmark (2)
Israel (2)
Japan (2)
Netherlands (2)
Singapore (2)
Taiwan (2)
Asia except Japan (1)
Austria (1)
Brazil (1)
Chile (1)
China (1)
Czechia (1)
Estonia (1)
Europe (1)
Georgia (1)
Ireland (1)
Latvia (1)
Lithuania (1)
Malaysia (1)
Moldova (1)

Keyword

CRC (9)
PDAC (8)
KRAS (6)
Gastrointestinal Neoplasms (3)
HNSCC (3)
Carboplatin (2)
Carcinoma, Pancreatic Ductal (2)
Gemcitabine (2)
Immunotherapy (2)
Intestinal Neoplasms (2)
Metastatic Cancer (2)
NRAS (2)
PD-1 (2)
Paclitaxel (2)
Pancreas (2)
Pancreatic Ductal Adenocarcinoma (2)
Pembrolizumab (2)
Pemetrexed (2)
Phase 1 (2)
Rectal Cancer (2)
Thoracic Neoplasms (2)
177Lu-FAP (1)
68Ga-FAP (1)
A2aR (1)
ATMP (1)
Abraxane 5 mg/ml powder for suspension for infusion (1)
Actinium (1)
Adenosine (1)
Adjuvant therapy (1)
Albumin-Bound Paclitaxel (1)

Previous page
1 / 777
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 777
Next page

Sort by:

Relevance

Page size

Metabolome profiling on resectable pancreatic ductal adenocarcinoma patients with early liver metastasis

Pancreatic ductal adenocarcinoma (PDAC) remains difficult to cure because many patients develop liver metastasis even after apparently curative resection. Bile is in close contact with the pancreatobiliary system, but its multi-omic features in resectable PDAC and their relationship to postoperative...

2026-10-17 | MTBLS15948 | MetaboLights

Mutations-Upstream-of-Metabolomic-Signature Based Functional Analyses Identify Prognostic Biomarkers and Therapeutic Targets in Pancreatic Ductal Adenocarcinoma

Cross-talk among downstream regulatory networks of genome mutations has been the major hypothetical mechanism underlying poor prognosis and low-responsive rates for targeted therapy of pancreatic ductal adenocarcinoma (PDAC). By applying a causal inference-based mutation-upstream-of-the-metabolom...

2025-10-13 | MTBLS13111 | MetaboLights

Mutations-Upstream-of-Metabolomic-Signature Based Functional Analyses Identify Prognostic Biomarkers and Therapeutic Targets in Pancreatic Ductal Adenocarcinoma

2025-10-13 | MTBLS13116 | MetaboLights

Mutations-Upstream-of-Metabolomic-Signature Based Functional Analyses Identify Prognostic Biomarkers and Therapeutic Targets in Pancreatic Ductal Adenocarcinoma

2025-10-13 | MTBLS13127 | MetaboLights

Microarray expression profile analysis of circular RNAs in human pancreatic ductal adenocarcinoma

To explore the potential involvement of circular RNAs (circRNAs) in pancreatic ductal adenocarcinoma (PDAC) oncogenesis, we conducted circRNA profiling in six pairs of human PDAC and adjacent normal tissue by microarray. Our results showed that clusters of circRNAs were aberrantly expressed in PDAC ...

ORGANISM(S): Homo sapiens

2015-11-20 | E-GEOD-69362 | biostudies-arrayexpress

ELAPOR1 induces the classical/progenitor subtype and contributes to reduced disease aggressiveness through metabolic reprogramming in pancreatic cancer

Pancreatic ductal adenocarcinoma (PDAC) is a heterogeneous disease with distinct molecular subtypes described as classical/progenitor and basal-like/squamous PDAC. We hypothesized that integrative transcriptome and metabolome approaches can identify candidate genes whose inactivation contributes to ...

2024-04-02 | MTBLS9418 | MetaboLights

KSN01_Proteome_CellLine: Aberrant (pro)renin receptor expression induces genomic instability in pancreatic ductal adenocarcinoma through upregulation of SMARCA5/SNF2H

Aberrant (pro)renin receptor expression induces genomic instability in pancreatic ductal adenocarcinoma through upregulation of SMARCA5/SNF2H

ORGANISM(S): Homo Sapiens (human)

2020-12-15 | PXD010107 | JPOST Repository

Identification of carcinogenesis and tumor progression processes in pancreatic ductal adenocarcinoma using high-throughput proteomics

Pancreatic adenocarcinoma (PDAC) is an aggressive disease with an overall 5 year-survival rate of just 5%. A better understanding of both the carcinogenesis processes and the mechanisms of progression of PDAC disease is mandatory. For this, proteomics data from FFPE samples of 173 primary tumor, nor...

ORGANISM(S): Homo Sapiens (ncbitaxon:9606)

2024-11-15 | MSV000096431 | MassIVE

Whole-Tissue Gene Expression Study of Pancreatic Ductal Adenocarcinoma

Expression analysis of 36 pancreatic ductal adenocarcinoma tumors and matching normal pancreatic tissue samples from pancreatic cancer patients of the Clinical Institute Fundeni (ICF) using Affymetrix U133 Plus 2.0 whole-genome chips. Pairs of normal and tumor tissue samples were obtained at the tim...

ORGANISM(S): Homo sapiens

2009-06-13 | E-GEOD-15471 | biostudies-arrayexpress

Genome-wide DNA methylation patterns in pancreatic ductal adenocarcinoma (PDAC)

Determine methylation pattern in PDAC a genome-wide analysis was performed in a cohort of 167 PDAC and 29 adjacent pancreatic tissues samples using the Infinium 450k methylation arrays (Illumina). 167 pancreatic tumors (PDAC) x 29 adjacent -non tumor samples.

ORGANISM(S): Homo sapiens

2014-07-08 | E-GEOD-49149 | biostudies-arrayexpress

Previous page
1 / 777
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 777
Next page

Sort by:

Relevance

Page size

7769 Results

Show results for

Organisms

Organisms

Repository

Tissue

Disease

Technology Type

Instrument Platform

Publication Date

CHEBI ID

Metabolite Name

First Public Date

Modification

Study status

Study type

Release Date

Lab affiliation

Location

Tags

Keyword

OmicsDI is part of the ELIXIR infrastructure

Tweets